Phase 2Completed

Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

Phase 2 Crossover, Randomized, Placebo-Controlled, Single-Blind, Repeat Dose Study in Post-Bariatric Hypoglycemia Subjects to Determine the Effect of Mizagliflozin on Adverse Events and Postprandial Glucose Excursions

Sponsor
Vogenx, Inc. (Industry)
Enrollment
15 enrolled
Conditions
Postbariatric Hypoglycemia
Interventions
Mizagliflozin; Placebo
Ages
adults, older adults
Registry
NCT05721729

Full record on ClinicalTrials.gov

From the registry

This is a phase 2 crossover, randomized, placebo-controlled, single-blind, repeat dose study in PBH subjects to determine the effect of mizagliflozin on adverse events and postprandial glucose excursions.

Primary outcomes

  • Glucose Nadir

History

  1. Results posted

  2. Last registry update

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered